RiverVest invites you to read our latest newsletter, featuring:
- Portfolio Company Avalyn Pharma Completes Upsized $345 Million IPO
- 2026 Annual Meeting Recap
- Atalanta Therapeutics: Reaching the Unreachable in Huntington’s Disease by Pascal Krotee, PhD
- Portfolio News